Jewell Christopher M 4
4 · Cartesian Therapeutics, Inc. · Filed Nov 21, 2024
Insider Transaction Report
Form 4
Jewell Christopher M
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-20$3.23/sh+14,000$45,220→ 39,940 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-20−14,000→ 76,432 totalExercise: $3.23Exp: 2033-01-15→ Common Stock (14,000 underlying)
Footnotes (2)
- [F1]The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.
- [F2]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.